Quest Diagnostics Inc
DGX · Healthcare · Health Care
Updated 26 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #342 of 500 by Iconic Score · #43 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Quest Diagnostics Inc (DGX) is a leading provider of diagnostic information services in the healthcare sector, specializing in clinical laboratory testing, pathology, and related services. With a market capitalization of $22.9 billion, Quest plays a crucial role in healthcare by delivering essential diagnostic insights that enable healthcare providers to make informed decisions for patient care. The company operates a vast network of laboratories and patient service centers, offering a comprehensive range of tests that support disease prevention, diagnosis, and treatment. Quest Diagnostics holds a strong market position, benefiting from its established reputation, extensive test menu, and commitment to innovation in diagnostic technology. As healthcare increasingly emphasizes data-driven decision-making, Quest's services are vital for improving patient outcomes and enhancing the overall efficiency of the healthcare system.
IconicOracleAI™ Brief
Quest Diagnostics Inc (DGX) currently holds an Iconic Score of 42, reflecting challenges in brand perception amid mixed market sentiment. Recent headlines highlight concerns over GeneDx's cash burn and questions about the effectiveness of rapid test growth in enhancing customer economics. However, partnerships aimed at improving cervical cancer screening access may bolster brand visibility, as indicated by a strong logo analysis score of 85/100. The company's market cap stands at $26.3 billion, with a recent price increase of 1.02%.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.